Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line Irinotecan Liposome in Pancreatic Cancer
NCT06700603Phase 2Not yet recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 2, open-label trial of irinotecan liposome in pancreatic ductal adenocarcinoma (PDAC) (2 cohorts). Primary endpoint: Progression-Free Survival at 1 year. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06700603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700603.